Antineutrophilic cytoplasmic antibody-associated vasculitis and the kidney.
Curr Opin Pediatr
; 34(2): 197-202, 2022 04 01.
Article
in English
| MEDLINE | ID: covidwho-1853279
ABSTRACT
PURPOSE OF REVIEW The purpose of this review is to highlight recent studies that have emerged on the topic of ANCA-associated vasculitis with some historical context. The review also discusses how the adult data is relevant to pediatric patients. RECENT FINDINGS:
Pediatric studies on AAV are lacking. Therapies targeted to the inflammatory cascade specifically implicated in AAV, such as MPO inhibitors and complement mediators, are emerging. The PEXIVAS study recently called into question the routine use of plasma exchange (PLEX) in severe AAV, with no difference in ESKD or mortality found between patients who did or did not receive PLEX. Longer maintenance duration of nearly 48âmonths is preferred as compared with shorter duration in patients who are not on dialysis because of higher relapse rates in children with AAV.SUMMARY:
Current treatment in AAV includes corticosteroids, rituximab, and cyclophosphamide for induction. Maintenance therapy commonly consists of azathioprine or rituximab. Plasma exchange (PLEX) is no longer recommended for induction therapy for AAV but some experts still consider this as an option for patients who are not responding to therapy or have severe disease at presentation. However, emerging novel therapies may be on the horizon.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Type of study:
Diagnostic study
Topics:
Long Covid
Limits:
Adult
/
Child
/
Humans
Language:
English
Journal:
Curr Opin Pediatr
Journal subject:
Pediatrics
Year:
2022
Document Type:
Article
Affiliation country:
MOP.0000000000001102
Similar
MEDLINE
...
LILACS
LIS